Updated on 3 February 2015
ABX464 is the candidate molecule for HIV treatment
Singapore: Abivax, a leading clinical stage biotech company developing and commercializing anti-viral compounds and human vaccines, has initiated the enrolment of HIV positive patients for a phase IIa clinical trial of ABX464.
ABX464 inhibits the biogenesis of viral RNA required for the replication of the HIV virus. In pre-clinical reference models of HIV, ABX464 demonstrated its ability to induce a substantial reduction in viral load that persists for weeks after treatment arrest.
Abivax highlighted that with current HIV treatments, the virus starts multiplying again as soon as the drugs are withdrawn, which typically means daily, life-long treatment for patients. ABX4646 needs to be administered less frequently over a shorter period than standard treatments, providing the potential to reduce healthcare costs and offer broader access to treatment.
Professor Mark Wainberg, former president, International AIDS Society, said, "If these unique features of ABX464 are confirmed in the clinical development program in HIV patients that is now underway, ABX464 could become the central element of a functional cure for AIDS."
The randomized, double-blind placebo-controlled clinical study, which is being conducted in Mauritius, is the first one of ABX464 in HIV patients and is designed to assess the safety and efficacy of the compound. It follows the successful completion of a Phase I clinical study in human volunteers in December 2014, which demonstrated that ABX464 was generally safe and well tolerated and had a favourable pharmacokinetic profile.